ERFO — Laboratorio Farmaceutico Erfo SpA Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapContrarian

Market Cap
€9.84m
Enterprise Value
€10.58m
Revenue
€9.49m

Annual income statement for Laboratorio Farmaceutico Erfo SpA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	4.82	4.62	5.74	5.83	9.49
Cost of Revenue
Gross Profit	2.6	2.35	2.41	2.33	3.46
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3.25	3.64	4.9	5.3	8.43
Operating Profit	1.57	0.987	0.837	0.524	1.07
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1.56	0.949	0.815	0.526	1.04
Provision for Income Taxes
Net Income After Taxes	1.17	0.716	0.59	0.353	0.737
Minority Interest
Net Income Before Extraordinary Items
Net Income	1.17	0.716	0.554	0.367	0.382
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1.17	0.716	0.554	0.367	0.382
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.131	0.08	0.067	0.057	0.075
Dividends per Share